Clin2
NCT04165590Possibly a fitRecruiting

Plasmodium immune treatment for advanced solid tumors

Advanced Malignant Solid Tumor

Part of Cancer, Infections clinical trials.

This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You’re age 18 to 70, and you have an advanced solid cancer (not a blood cancer).
  • Your cancer is in the lungs, liver, prostate, ovary, brain, thyroid, colon, or similar solid sites.
  • If you have brain tumors or brain metastases, you must be stable on scans for at least 3 months and have no recent bleeding in the brain.
  • Your cancer has measurable spots on scans, and a pathology report confirms the cancer type.
  • You must have enough blood counts and organ function (heart/lung/liver/kidneys) to safely take study treatment.
  • You must be able to sign consent and attend follow-up visits.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07337525Recruiting· Phase 1
First study of PLT012 in advanced solid tumors

This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.

Los Angeles, California
NCT07594028Not yet recruiting· Phase 1/Phase 2
Cell therapy plus immunotherapy for advanced solid tumors

This trial tests a combination of two cell-based therapies (SCTB41 and SCTB39-1) with or without standard cancer treatments for advanced solid tumors. The goal is to see if this approach helps slow or shrink tumors while being safe enough to use in patients.

NCT05924776Not yet recruiting· Phase 2/Phase 3
Plasmodium immunotherapy for advanced platinum-resistant ovarian cancer

This trial tests Plasmodium immunotherapy in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the treatment can slow tumor growth or improve cancer control.

Guangzhou, Guangdong
NCT03375983Recruiting· Phase 1/Phase 2
Immune treatment with malaria cells for advanced solid cancers

This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.

Guangzhou, Guangdong
NCT03474822Recruiting· Phase 1/Phase 2
Plasmodium immune treatment for breast and liver cancers

This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.

Guangzhou, Guangdong
NCT06716619Recruiting· Phase 1
Immune cell therapy for advanced solid tumors

This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.

Guangzhou, Gaungdong

Hear when a new Advanced Malignant Solid Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.